Get started
CHONGQING LUMMY PHCC

CHONGQING LUMMY PH

3.46CNYD
−0.26−6.99%
At close at 08:50 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

300006 fundamentals

Key facts

Market capitalization‪3.93 B‬CNY
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.08CNY
Founded1999
Employees (FY)‪1.02 K‬
CEORong Zhao Qiu
Websitecqlummy.com
About

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and sale of pharmaceuticals. Its products include tumor drugs, antibacterial drugs, antifungal drugs, antiviral agents, digestive system agents, immune system agents, blood system agents, cardiovascular system agents, nervous system agents, electrolyte and acid-base balance and nutritional, liver disease auxiliary drugs, endocrinology system drugs, Chinese patent drugs, base large infusion, American ginseng, and active pharmaceutical ingredients. The company was founded on September 6, 1999 and is headquartered in Chongqing, China.

Ownership
‪‪1.06 B‬‬
Free Float shares
‪‪888.58 M‬‬ (84.15%)
Closely held shares
‪‪167.33 M‬‬ (15.85%)
Free Float shares
‪‪888.58 M‬‬ (84.15%)
Closely held shares
‪‪167.33 M‬‬ (15.85%)
Capital structure
Market cap
‪‪3.93 B‬‬
Debt
‪‪494.59 M‬‬
Minority interest
‪‪8.04 M‬‬
Cash & equivalents
‪‪1.07 B‬‬
Enterprise value
‪‪3.36 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪3.93 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
5.05x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
5.05x
Valuation ratios
‪0.00‬
‪1.20‬
‪2.40‬
‪3.60‬
‪4.80‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪50.00‬
‪100.00‬
‪150.00‬
‪200.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−34%‬
‪−17%‬
‪0%‬
‪17%‬
‪34%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−90.00 M‬‬
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−80.00 M‬‬
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Specialties
Pharmaceutical Distribution
Anti-infection
Other Business
Other Varieties
Service Income
By country
Period: 2024
China

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2019
2020
2021
2022
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Estimate
Earnings
Next:—
2019
2020
2021
2022
‪−0.45‬
‪−0.30‬
‪−0.15‬
‪0.00‬
‪0.15‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
—
Last ex-date
—
Dividend history
‪0%‬
2020
2021
2022
2023
2024
‪0.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−400.00 M‬‬
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Assets
Liabilities